Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

The investigators will carry out a prospective study in patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes will be treated with intravitreal injection of bevacizumab (1.25 mg). Complete ophthalmic examination and/or ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection. Re-injection will be done in non-clearing and recurrent VH.

Inclusion Criteria:

• patients with diabetes mellitus
• proliferative diabetic retinopathy
• prior complete panretinal photocoagulation
• presented with new dense vitreous hemorrhage

Exclusion Criteria:

• one-eyed patient
• previous intraocular surgery
• severe lens opacity precluding fundus examination
• advance glaucoma
• history of thromboembolic events such as myocardial infarction and cerebrovascular accident
• uncontrolled systemic hypertension, systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg
• known coagulation abnormalities or current use of anticoagulant medications other than aspirin
• known allergies to any relevant drugs in this study
• evidence of external ocular infection such as conjunctivitis and significant blepharitis.